Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

12.3K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
12.3K
Clinical Trials01:16

Clinical Trials

6.6K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
6.6K
Drug Discovery: Overview01:26

Drug Discovery: Overview

7.3K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.3K
Clinical Trials: Overview01:11

Clinical Trials: Overview

2.6K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.6K
Pharmacovigilance01:19

Pharmacovigilance

762
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
762
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

206
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
206

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Insight into the role of 3D reconstruction of MRI imaging for complex anogenital hidradenitis suppurativa: A single-center case series.

JPRAS open·2026
Same author

The Children's Urgent Reduction of Forearm Fractures in the Emergency Department (CURFFED) project : a national prospective trainee-led collaborative audit of practice.

Bone & joint open·2026
Same author

Modifying muscle metabolic dysregulation in inclusion body myositis with pioglitazone: a single-arm trial.

Nature communications·2026
Same author

Haemodynamic impact of implant materials and anastomotic angle in femoro-popliteal artery grafts.

Biomechanics and modeling in mechanobiology·2026
Same author

Dual probe ligation in situ hybridization with rolling-circle amplification for high-plex spatial transcriptomics.

Biochemistry and biophysics reports·2025
Same author

Optimism in inclusion body myositis: a double-blind randomised controlled phase III trial investigating the effect of sirolimus on disease progression in patients with IBM as measured by the IBM Functional Rating Scale.

Clinical and experimental rheumatology·2025

Related Experiment Video

Updated: Jul 9, 2026

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

Enhancing clinical research with pharmacogenomics: a practical perspective.

Xiaolong Tom Zhang1, Jacob Blacutt1, Thomas Lloyd1

  • 1Early Phase Unit, Worldwide Clinical Trials, Austin, TX, USA.

Bioanalysis
|March 22, 2025
PubMed
Summary

Pharmacogenomics (PGx) research integrates genetic insights into drug development for improved safety and efficacy. This review outlines PGx strategies, technologies, validation, and regulatory aspects for clinical trials.

Keywords:
PGx platformPharmacogenomicsdrug metabolismdrug targetdrug transportgenetic biomarkerpersonalized medicinephenotype

More Related Videos

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

Related Experiment Videos

Last Updated: Jul 9, 2026

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

Area of Science:

  • Pharmacogenomics
  • Clinical Research
  • Drug Development

Background:

  • Genetic variations significantly impact drug response, safety, and efficacy.
  • Pharmacogenomics (PGx) offers a pathway to optimize therapeutic development.
  • Understanding these genetic influences is crucial for personalized medicine.

Purpose of the Study:

  • To provide a structured analysis of pharmacogenomics in clinical research.
  • To offer a practical framework for integrating PGx into drug development.
  • To enhance drug safety, efficacy, and personalized medicine through PGx.

Main Methods:

  • Overview of key genes in drug metabolism, transport, and targets.
  • Examination of strategies for identifying PGx-relevant genes (phenotype-driven, hypothesis-driven, population-focused, clinical-driven).
  • Analysis of technical platforms (PCR, MassARRAY, NGS) and assay validation processes (analytical, clinical).

Main Results:

  • Identification of key genes and strategies for PGx research.
  • Evaluation of suitable technical platforms and validation requirements.
  • Discussion of regulatory expectations for PGx across all drug development phases.

Conclusions:

  • Integrating PGx into clinical research requires a structured approach.
  • Robust validation and understanding of regulatory expectations are essential for successful PGx implementation.
  • Pharmacogenomics is pivotal for advancing personalized medicine and optimizing drug therapies.